Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.82% is 1090% above its 5-year average of -0.49%, near the high end of its 5-year range (-6.12%–4.82%).
66.78% above its 12-month average of 2.89%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.44%.
RETURN ON ASSETS (ROA)
4.82%
RETURN ON ASSETS (ROA) AVG TTM
2.89%
RETURN ON ASSETS (ROA) AVG 3Y
-0.31%
RETURN ON ASSETS (ROA) AVG 5Y
-0.49%
RETURN ON ASSETS (ROA) AVG 10Y
-12.33%
RETURN ON ASSETS (ROA) AVG 15Y
-17.81%
RETURN ON ASSETS (ROA) AVG 20Y
-28.31%
CURRENT VS TTM AVG
+66.78%
CURRENT VS 3Y AVG
+1654.84%
CURRENT VS 5Y AVG
+1090.41%
CURRENT VS 10Y AVG
+139.09%
CURRENT VS 15Y AVG
+127.06%
CURRENT VS 20Y AVG
+117.02%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+114.95%
vs the sector median at left
Vericel Corporation
Market Cap
$2.06B
Return on Assets (ROA)
4.82%
TTM Avg
2.89%
3Y Avg
-0.31%
5Y Avg
-0.49%
Market Cap
$2.06B
Return on Assets (ROA)
-35.27%
TTM Avg
-37.23%
3Y Avg
-38.20%
5Y Avg
-46.02%
Market Cap
$2.07B
Return on Assets (ROA)
-38.42%
TTM Avg
-32.16%
3Y Avg
-31.63%
5Y Avg
-27.96%
Market Cap
$2.07B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.04B
Return on Assets (ROA)
-38.65%
TTM Avg
-60.49%
3Y Avg
-64.82%
5Y Avg
-76.19%
Market Cap
$2.04B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.09B
Return on Assets (ROA)
-75.40%
TTM Avg
-31.99%
3Y Avg
-46.60%
5Y Avg
-53.88%
Market Cap
$2.03B
Return on Assets (ROA)
10.98%
TTM Avg
8.41%
3Y Avg
7.65%
5Y Avg
11.22%
Market Cap
$2.03B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vericel Corporation (VCEL) | $2.06B | 4.82% | 2.89% | -0.31% | -0.49% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -35.27% | -37.23% | -38.20% | -46.02% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | -38.42% | -32.16% | -31.63% | -27.96% |
| Alvotech (ALVO)vs › | $2.07B | -11.31% | -8.55% | -34.29% | -31.66% |
| UroGen Pharma Ltd. (URGN)vs › | $2.04B | -38.65% | -60.49% | -64.82% | -76.19% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | -68.96% | 16.60% | -13.89% | -23.58% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | -75.40% | -31.99% | -46.60% | -53.88% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 10.98% | 8.41% | 7.65% | 11.22% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.03B | -3.14% | -22.75% | -10.43% | -6.58% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 39.65% | 19.63% | 0.51% | -8.90% |
ROA
4.8%
ROE
6.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.39% |
| 2024-12-31 | 2.39% |
| 2023-12-31 | -0.90% |
| 2022-12-31 | -6.12% |
| 2021-12-31 | -3.07% |
| 2020-12-31 | 1.39% |
| 2019-12-31 | -6.31% |
| 2018-12-31 | -6.86% |
| 2017-12-31 | -31.67% |
| 2016-12-31 | -40.26% |
| 2015-12-31 | -47.63% |
| 2014-12-31 | -41.87% |
| 2013-12-31 | -169.53% |
| 2012-12-31 | -194.19% |
| 2011-12-31 | -254.14% |
| 2010-12-31 | -54.01% |
| 2010-06-30 | -82.72% |
| 2008-06-30 | -76.79% |
| 2007-06-30 | -53.56% |
| 2006-06-30 | -36.71% |
| 2005-06-30 | -34.84% |
| 2004-06-30 | -57.73% |
| 2003-06-30 | -78.81% |
| 2002-06-30 | -68.72% |
| 2001-06-30 | -49.78% |
| 2000-06-30 | -69.88% |
| 1999-06-30 | -115.60% |
| 1998-06-30 | -139.27% |
| 1997-06-30 | -68.38% |
| 1996-06-30 | -162.30% |
